Those evaluating the broader GLP-1 landscape may also want to consider retatrutide, the investigational triple-agonist with preliminary data showing greater weight loss than any approved therapy.
When certain medical conditions are in play, they can completely change the game, making a structured, long-term plan necessary
If youre disclosing everything everywhere all at once, then you need to do earlier planning for registration and results, you need to think about the plain language summaries, youre doing a lot more coordination across the organization, he said
BPC-157 and TB-500 are not pharmaceuticals, dietary supplements, or cosmetics
SELECT established Semaglutide as CV-protective therapy, CagriSema must demonstrate at least equivalent CV safety for broad clinical practice